Stock Groups

China to strengthen anti-monopoly efforts in pharma industry -Breaking

by Mike Robinson

[ad_1]

© Reuters. A pharmacy in Shanghai, China displays shelves containing medicines. November 27, 2015. REUTERS/Aly Son/File Photo

BEIJING, (Reuters) – China is expected to tighten its law enforcement in order to curtail monopoly practices as well as unfair competition within the pharmaceutical sector. This move was made by the ministry of industry on Sunday.

It follows the November regulatory guidelines that aim to eradicate monopolies in active pharmaceutical ingredient (API). China is the largest exporter and manufacturer of these products in the world.

The ministry of industry, information technology stated in a statement that it will “strengthen law Enforcement against unfair Competition, and resolutely probe unfair Competitive Acts, like commercial Bribery”.

The law will be enforced more strictly in areas like drug shortages and APIs. It also prepares and adopts antitrust guidelines for the API market. Additionally, the investigation of monopolistic agreements is being done.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]